Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel

Core Viewpoint - Scilex Holding Company has appointed Kasowitz LLP and its founding partner Marc Kasowitz as its litigation and intellectual property counsel to enhance its legal capabilities in protecting and advancing its proprietary pharmaceutical assets and development pipeline [1][2][3]. Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for treating acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [4][7]. - The company targets high unmet needs and large market opportunities with non-opioid therapies, aiming to improve patient outcomes [4]. Product Portfolio - Scilex's commercial products include: - ZTlido (lidocaine topical system) 1.8%, approved by the FDA for neuropathic pain relief associated with postherpetic neuralgia [4]. - ELYXYB, the only FDA-approved ready-to-use oral solution for acute migraine treatment in adults [4]. - Gloperba, the first liquid oral version of colchicine for the prophylaxis of painful gout flares in adults [4]. - The company has three product candidates in development: - SP-102 (SEMDEXA™), a viscous gel formulation for epidural injections to treat lumbosacral radicular pain, which has completed a Phase 3 study and received Fast Track status from the FDA [5]. - SP-103, a next-generation lidocaine topical system for acute pain, which has completed a Phase 2 trial and also received Fast Track status [6]. - SP-104, a novel low-dose delayed-release naltrexone for fibromyalgia treatment [6]. Legal Counsel Appointment - Kasowitz LLP will provide advice on complex commercial litigation, patent litigation, intellectual property enforcement, and licensing matters [2]. - Marc Kasowitz is recognized for his expertise in high-stakes intellectual property and complex commercial litigation, enhancing Scilex's legal strategy [3].